ImClone Systems, Inc.
http://www.imclone.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ImClone Systems, Inc.
No OS Gain For 34 China-Approved Cancer Drug Indications
Sweeping regulatory reforms put China in catch-up mode for the approval of oncology drugs, some of which have been cleared for marketing only in the country. But how does the deluge of new products measure up in terms of actual overall survival benefits? A new study by Peking University scholars and specialists unveils some surprising results.
EQRx Revises Plans To Get Chinese Licensed Drugs To US Market
The company has filed its first drug in the UK and initiated a US-based Phase III trial; US drug pricing legislation underscores the company's value proposition, CEO says.
EQRx Revises Plans To Get Chinese Licensed Drugs To US Market
The company has filed its first drug in the UK and initiated a US-based Phase III trial; US drug pricing legislation underscores the company's value proposition, CEO argues, since payers will still be under pressure.
Sanofi, Innovent Link On China Oncology Ambitions As ADCs Surge
The antibody-drug conjugate market is emerging as the next battleground for intense competition in China, with global partnerships becoming essential to win, as evidenced by a major new alliance between Innovent and Sanofi.